8 June 2016
Webinar - Progress on building a tool for predicting the purging of mutagenic impurities during synthesis
Still in its project phase, Mirabilis is the result of a continuing collaboration between Lhasa Limited and various pharmaceutical industry partners, to develop a systematic approach for the risk assessment of potentially mutagenic impurities remaining in a final drug product when introduced or created during synthesis.
In this webinar, Andrew Teasdale of AstraZeneca provided an overview on the continued development of Mirabilis.
His presentation featured an introduction to the purge tool concept and how it relates to ICH M7, illustrative examples and an overview on his experience on the use of purge for regulatory submissions. Andy concluded by providing an update on the continued development of Mirabilis.
Following his presentation, William Drewe of Lhasa Limited provided a short demonstration of the latest version of Mirabilis.
Headline Event (shown first above featured)